| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/CHMP/48716/2012 (20.1.12) |
| Publication Date | 20/01/2011 |
| Content Type | News |
|
The European Medicines Agency (EMA) announced, on 20 January 2012, that it had begun a review of the benefits and risks of the multiple-sclerosis medicine Gilenya. This followed concerns over the effects of the medicine on the heart after the first dose. |
|
| Source Link | Link to Main Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/01/news_detail_001425.jsp&mid=WC0b01ac058004d5c1 |
| Related Links |
|
| Subject Categories | Health |
| Countries / Regions | Europe |
